Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quiz
Press Releases
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Articles
Articles
Dual HER2 Blockade with Pertuzumab Substantially Delays Disease Progression
By
Caroline Helwick
CTRC-AACR SABCS Annual Meeting
December 2011, Vol 2, No 7
San Antonio, TX—It is becoming increasingly clear that 2 agents are better than 1 in treating HER2-positive advanced breast cancer.
Read More
GPCI, or “GYPSY”: Calculated or Covert Cuts to Oncology Reimbursement
By
Robert Gamble
Health Policy
,
Policies & Guidelines
December 2011, Vol 2, No 7
Read More
Frontier Cancer Care in Montana on the Leading Edge of Patient Care
Best Practices
,
Policies & Guidelines
December 2011, Vol 2, No 7
Interview with Patrick Cobb, MD, FACP
Read More
Recent Ruling on Genetic Patents Leaves Many Questions
By
Rosemary Frei, MSc
Health Policy
,
Policies & Guidelines
October 2011, Vol 2, No 6
On July 29, 2011, a 3-judge panel from the US Court of Appeals for the Federal Circuit invalidated some patents held by Myriad Genetics and the University of Utah Research Foundation for methods of analyzing individuals’ gene sequences for the presence of BRCA1 and BRCA2 mutations, but upheld other related patents in a reversal of a lower court ruling.
Read More
Concurrent Chemotherapy and Radiation Therapy Extends Survival in NSCLC
In the Literature
October 2011, Vol 2, No 6
The concurrent use of chemotherapy and thoracic radiotherapy (TRT) confers a greater survival benefit in patients with stage III non–small-cell lung cancer (NSCLC) than a sequential use of these therapies, based on results from a phase 3 clinical study (Curran WJ, et al. J Natl Cancer Inst. 2011;103: 1452-1460).
Read More
Survivorship Programs an Emerging Need, But Are They Cost-Effective?
By
Caroline Helwick
Policies & Guidelines
,
Survivorship Care
October 2011, Vol 2, No 6
The population of cancer survivors is rapidly growing. More than 12 million Americans are alive after a cancer diagnosis: most are living at least 5 years and 16% are alive 20 years after diagnosis.
Read More
Order of Initial Breast Cancer Treatment Does Not Affect Outcomes
By
Audrey Andrews
Breast Cancer Symposium
October 2011, Vol 2, No 6
Whether women receive chemotherapy or surgery first as their initial treatment for breast cancer does not affect long-term localregional recurrence, according to a large case series from the University of Texas M.D. Anderson Cancer Center, Houston, that was presented at the 2011 Breast Cancer Symposium.
Read More
Occult Metastases Do Not Warrant Axillary Dissection in Breast Cancer
By
Audrey Andrews
Breast Cancer Symposium
October 2011, Vol 2, No 6
San Francisco, CA—The debate over the clinical significance of occult micrometastases in the lymph nodes of patients with breast cancer continues.
Read More
Targeted Radiation Therapy Gaining Momentum
By
Caroline Helwick
ASCO Breast Cancer Symposium
October 2011, Vol 2, No 6
San Francisco, CA—Accelerated partial breast irradiation using brachytherapy (APBIb) for breast cancer has been rapidly adopted in the United States, although its use varies by region, race, and ethnicity. Jona A. Hattangadi, MD, Harvard Radiation Oncology Program, Boston, reported the findings at the 2011 ASCO Breast Cancer Symposium, which was sponsored by 6 breast, oncology, and surgical societies.
Read More
Breast Cancer Treatment Still Under Par for Patients Covered by Medicaid
By
Audrey Andrews
Breast Cancer Symposium
October 2011, Vol 2, No 6
San Francisco, CA—Several studies presented at the 2011 Breast Cancer Symposium shed light on the quality of breast cancer care received by women who are uninsured or receiving Medicaid.
Read More
Page 304 of 329
301
302
303
304
305
306
307
Top Trending Articles
1.
Immunotherapy Helps Navy Veteran Beat Stage 4 Lung Cancer
2.
HOPA Highlights: What's New in 2025?
3.
AUGTYRO (Repotrectinib) for the Treatment of ROS1-Positive Non-Small Cell Lung Cancer
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quiz
Press Releases
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma